Everand Logo

Welcome to Everand!

  • STAT

    A PAC is using the midterms to spotlight high drug prices. Why is it sinking millions into unwinnable races?

    A political action committee that’s singularly focused on high drug prices is shelling out millions in races that have already been decided. Here’s why.
    by Rebecca Robbins and Lev Facher Oct 05, 2018 7 minutes

    SAN FRANCISCO — In 26 years in Congress, Rep. Anna Eshoo has always won reelection by at least 20 points. The Democrat is virtually certain to win big once again in November, buoyed largely by voters in her wealthy Silicon Valley district who do not struggle to pay for their prescription drugs.

    So why is a political action committee focused on high drug prices bothering to sink $500,000 into attack ads against her?

    The ad blitz from Patients for Affordable Drugs highlights the unorthodox tack the group is taking in the 2018 midterm elections: intervening in races in which there is no hope of altering the outcome.

    Of the nine congressional and gubernatorial races in which P4AD has supported or opposed candidates to date, just three or four are competitive, according to STAT’s analysis of election forecasts from the website FiveThirtyEight.

    And of the at least $8 million the group has spent in total, as much as $6 million has gone to the races in which the outcome has long been determined.

    P4AD, which is funded mainly by the billionaire Houston couple , says that where its money can’t help decide a race, it can still send a message: that

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT1 min read
    USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
    With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
    STAT1 min read
    Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
    To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

    Related Books & Audiobooks